| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 02/28/2007 | EP1755539A2 Flavivirus vaccines |
| 02/28/2007 | EP1436002B1 Use of peptide vectors to improve the immune response to antigens |
| 02/28/2007 | EP1401493B1 Subunit vaccines and processes for the production thereof |
| 02/28/2007 | EP1381397B1 Stabilisation of radiopharmaceutical compositions using a hydrophilic thioether or a hydrophilic 6-hydroxy chroman |
| 02/28/2007 | EP1254240B1 Hybrid protease with reduced antigenicity and its use |
| 02/28/2007 | EP1248848B1 Methods and materials relating to stem cell growth factor-like poypeptides and polynucleotides |
| 02/28/2007 | EP1240317B1 Nucleic acid vaccination |
| 02/28/2007 | EP1189634B1 Treating prostate cancer with anti-erbb2 antibodies |
| 02/28/2007 | EP1151756B1 Kit comprising polyacrylamide gel for forming a capsule in the tissue of a mammal organism and allogenic or xenogenous cells of an animal, method for therapy of oncological diseases and the diabetes mellitus |
| 02/28/2007 | EP1077999B1 Moraxella catharralis proteins |
| 02/28/2007 | EP1073737B1 Immunosuppression by blocking t cell co-stimulation signal 2 (b7/cd28 interaction) |
| 02/28/2007 | EP1025209B1 An attenuated japanese encephalitis virus adapted to vero cell and a japanese encephalitis vaccine |
| 02/28/2007 | EP1024827B1 Compositions and methods for systemic delivery of oral vaccines and therapeutic agents |
| 02/28/2007 | EP0938497B1 Constrained helical peptides and methods of making same |
| 02/28/2007 | EP0909323B1 Helicobacter pylori bacterioferritin |
| 02/28/2007 | EP0888122B1 HYBRID WITH INTERFERON-alpha AND AN IMMUNOGLOBULIN Fc LINKED THROUGH A NON-IMMUNOGENIC PEPTIDE |
| 02/28/2007 | EP0770628B9 Reconstituted human antibody against human interleukin-8 |
| 02/28/2007 | CN1922324A Bacterial virulence factors and uses thereof |
| 02/28/2007 | CN1922316A Mutants of anti-cd40 antibody |
| 02/28/2007 | CN1922309A A respiratory syncytial virus with a genomic deficiency complemented in trans |
| 02/28/2007 | CN1922209A Anti-ab antibody |
| 02/28/2007 | CN1922205A Galanin receptors and brain injury |
| 02/28/2007 | CN1922202A Lsa-5 liver stage and blood stage antigen of plasmodium falciparum, immunogenic composition comprising said antigen, and vaccines against malaria |
| 02/28/2007 | CN1922199A Ca6 antigen-specific cytotoxic conjugate and methods of using the same |
| 02/28/2007 | CN1921886A Methods of modulating cytokine activity, related reagents |
| 02/28/2007 | CN1921884A Recombinant nucleic acid molecules, expression cassettes, and bacteria, and methods of use thereof |
| 02/28/2007 | CN1921883A Vaccine comprising an angiomotin or a polynucleotide encoding an angiomotin and its use for the treatment of angiogenic-related disorders |
| 02/28/2007 | CN1921882A Allogeneic tumor therapeutic agent |
| 02/28/2007 | CN1921878A Proteins belonging to the bcl-2 family and fragments thereof, and their use in cancer patients |
| 02/28/2007 | CN1921862A Immunostimulant composition comprising at least one TOLL-like receptor 7 or TOLL-like receptor 8 agonist and a TOLL-like receptor 4 agonist |
| 02/28/2007 | CN1919871A B7. 1-CD19scFv fusion gene engineering albumen for treating B lymphocyte leukemia and lymph tumour and use thereof |
| 02/28/2007 | CN1919342A Canine tumor treatment method, pharmaceutical formulation applied thereto, and method of cryogenically preserving cells used therewith |
| 02/28/2007 | CN1919341A Application of hepatitis B surface antigen-antibody complexes in preparing prophylaxis product with no response or low response to hepatitis B vaccine |
| 02/28/2007 | CN1919340A Hydrophobia split vaccine for human body |
| 02/28/2007 | CN1302103C CD 19XCD3 specific polypeptides and uses thereof |
| 02/28/2007 | CN1301749C Polyepitope DNA vaccine of anti-simple herpes virus-2 infection and its preparing method |
| 02/28/2007 | CA2519535A1 Development of natural killer cells and functional natural killer cell lines |
| 02/27/2007 | USRE39494 Vaccine mixture of attenuated or killed immunogen of Mycoplasma hypopneumoniae bacteria, and Bordetella or Pasteurella vaccine against swine disease; diagnosis |
| 02/27/2007 | US7183404 Infectious salmon anaemia (ISA); genetic vaccine comprising cDNA coding for immunogenic proteins from ISA virus; ISA is a viral disease that affects Atlantic salmon in cultivation |
| 02/27/2007 | US7183402 Chlamydia antigens and corresponding DNA fragments and uses thereof |
| 02/27/2007 | US7183400 Use of ULIP proteins in the diagnosis and therapy of cancers and paraneoplastic neurological syndromes |
| 02/27/2007 | US7183390 Humanized antibodies to gamma-interferon |
| 02/27/2007 | US7183389 Monoclonal antibodies and cell surface antigens for the detection and treatment of small cell lung cancer (SCLC) |
| 02/27/2007 | US7183388 Anti-MUC-1 single chain antibodies for tumor targeting |
| 02/27/2007 | US7183379 Human leucine-rich repeat containing protein expressed predominately in small intestine, HLRRSI1 |
| 02/27/2007 | US7183376 Variant B7 co-stimulatory molecules |
| 02/27/2007 | US7183111 Immunomodulatory formulations and methods for use thereof |
| 02/27/2007 | US7183107 Enhanced replication of HCV RNA |
| 02/27/2007 | US7183101 NCC2705—the genome of a bifidobacterium |
| 02/27/2007 | US7183083 Nucleic acid and amino acid sequences relating to Staphylococcus epidermidis for diagnostics and therapeutics |
| 02/27/2007 | US7183075 Purified and isolated potassium-chloride cotransporter nucleic acids and polypeptides and therapeutic and screening methods using same |
| 02/27/2007 | US7183051 Diagnosis and treatment of cancer |
| 02/27/2007 | US7182948 Topical veterinary compositions and methods for the treatment and prevention of infection |
| 02/27/2007 | US7182947 Papillomavirus truncated L1 protein and fusion protein constructs |
| 02/27/2007 | US7182946 monoclonal antibody produced by the hybridoma cell line 57D2, deposited in accordance with the Budapest treaty under the number DSM ACC2568, or a fragment of |
| 02/27/2007 | US7182942 Vaccine immunotherapy for immune suppressed patients |
| 02/27/2007 | US7182933 Biomolecule carrier bearing molecules that bind to a cellular adhesion molecule expressed on endothelial cell |
| 02/27/2007 | CA2098253C Method for producing ectoprotein of hepatitis c virus |
| 02/23/2007 | CA2513027A1 Method of inhibiting vascular permeability |
| 02/22/2007 | WO2007022520A2 Antibody-mediated enhancement of immune response |
| 02/22/2007 | WO2007022477A2 Methods and compositions to generate and control the effector profile of t cells |
| 02/22/2007 | WO2007022475A1 Fas binding antibodies |
| 02/22/2007 | WO2007022425A2 Influenza recombinant subunit vaccine |
| 02/22/2007 | WO2007022424A2 Laminin receptor targeting method for delivering a toxic agent inside a cell |
| 02/22/2007 | WO2007022416A2 Single chain antibodies against beta-amyloid peptide |
| 02/22/2007 | WO2007022172A1 Human monoclonal antibodies that specifically bind igf-ii |
| 02/22/2007 | WO2007022152A2 Lipid nano particulates containing antigens as cancer vaccines |
| 02/22/2007 | WO2007022053A2 Methods and compositions for dried cellular forms |
| 02/22/2007 | WO2007021841A2 Identification and engineering of antibodies with variant fc regions and methods of using same |
| 02/22/2007 | WO2007021672A2 Vaccination against dengue virus infection |
| 02/22/2007 | WO2007021317A1 Detecting molecular complexes |
| 02/22/2007 | WO2007020965A1 Method of inhibiting function of cytosolic protein by single chain antibody and use thereof |
| 02/22/2007 | WO2007020935A1 Therapeutic agent for pain comprising p2y12 receptor and/or p2y14 receptor blocker |
| 02/22/2007 | WO2007020509A1 Combination of methylol transfer agents with tumour-inhibiting proteins or peptides and the use thereof for the treatment of cancer or tumor growth |
| 02/22/2007 | WO2007020018A1 Use of purinergic and pyrimidinergic receptor agonists for dendritic cells based immunotherapies |
| 02/22/2007 | WO2007020017A1 Composition for bird immunization administered by aerosol |
| 02/22/2007 | WO2007019901A1 Food products comprising probiotic micro-organisms and antibodies |
| 02/22/2007 | WO2007019621A1 Chimeric antibodies with new world primate regions |
| 02/22/2007 | WO2007019620A1 Engineered antibodies with new world primate framework regions |
| 02/22/2007 | WO2007019618A1 Phrophylactic and/or therapeutic method for treatment of autoimmune disease |
| 02/22/2007 | WO2006138553A3 Methods of purifying fc region containing proteins |
| 02/22/2007 | WO2006135385A3 Antagonizing interleukin-21 receptor activity |
| 02/22/2007 | WO2006131562A3 Diagnostic and therapeutic target cdc2l6 gene and proteins for neurodegenerative diseases |
| 02/22/2007 | WO2006125632A3 Agonistic antibodies that bind to the tweak receptor fn14 and thereby modulate adiposity-associated phenotypes as well as their use in therapy |
| 02/22/2007 | WO2006125229A8 Use of tnf inhibitor for treatment of erosive polyarthritis |
| 02/22/2007 | WO2006120474A3 Compositions for inducing an immune response against tumor antigens |
| 02/22/2007 | WO2006118916A3 Methods and compositions for polytopic vaccination |
| 02/22/2007 | WO2006104911A3 Methods and compositions for modulating hyperstabilized c-met |
| 02/22/2007 | WO2006103472A3 Soluble vox2 protein as immunoregulatory factor |
| 02/22/2007 | WO2006091515A3 Tumour vaccines |
| 02/22/2007 | WO2006086638A3 Targeting lipocalin-2 for cancer therapeutics |
| 02/22/2007 | WO2006084007A3 Novel gene underlying atherosclerosis locus i |
| 02/22/2007 | WO2006071441A3 Antibodies directed to gpnmb and uses thereof |
| 02/22/2007 | WO2006069202A3 Compositions comprising anti-igf-i receptor antibodies and methods for obtaining said antibodies |
| 02/22/2007 | WO2006066065A3 Irreversibly-inactivated pepsinogen fragment and pharmaceutical compositions comprising this fragment for detecting, preventing, and treating hiv |
| 02/22/2007 | WO2006063055A3 Enzyme conjugates for use as detoxifying agents |
| 02/22/2007 | WO2006063028A3 Immunostimulatory compositions and uses thereof |
| 02/22/2007 | WO2006060710A3 Vaccine formulations for intradermal delivery comprising adjuvants and antigenic agents |
| 02/22/2007 | WO2006058243A3 Leishmania antigens and related compositions and uses |
| 02/22/2007 | WO2006047673A3 Mammalian genes involved in infection |